|
[1] ZHANG L,WANG F,WANG L,et al.Prevalence of chronic kidney disease in China:a cross-sectional survey[J].Lancet,2012,379(9818):815-822.
|
|
[2]CAI J,FAN X,MOU L,et al.Association of reduced renal function with hepatitis B virus infection and elevated alanine aminotransferase[J].Clin J Am Soc Nephrol,2012,7(10):1561-1566.
|
|
[3]CHEN YC.13-year nationwide cohort study of chronic kidney disease risk among treatment-na6ve patients with chronic hepatitis B in Taiwan[J].BMC Nephrol,2015,16(1):110.
|
|
[4]CHEN XM,SUN XF,CAI GY.Public health policies for prevention and treatment of chronic kidney disease in China[J].Natl Med J China,2014,94(4):241-243.(in Chinese)陈香美,孙雪峰,蔡广研.我国慢性肾脏病防治的公共健康政策思考[J].中华医学杂志,2014,94(4):241-243.
|
|
[5]ZHANG LX,ZUO L,XU GB,et al.Community-based screening for chronic kidney disease among population older than 40 years in Beijing[J].Chin J Nephrol,2006,22(2):67-71.(in Chinese)张路霞,左力,徐国宾,等.北京市石景山地区中老年人群中慢性肾脏病的流行病学研究[J].中华肾脏病杂志,2006,22(2):67-71.
|
|
[6] HOU JL.A brief introduction of standard medical kit for hepatitis B[EB/OL].[2015-05-25].http://www.cfhpc.org/upload/ppt/20150525223338670.pdf.(in Chinese)侯金林.乙肝标准治疗包简介[EB/OL].[2015-05-25].http://www.cfhpc.org/upload/ppt/20150525223338670.pdf.
|
|
[7]FERNANDEZ-FERNANDEZ B,MONTOYA-FERRER A,SANZ AB,et al.Tenofovir nephrotoxicity:2011 update[J].AIDS Res Treat,2011,2011:354908.
|
|
[8]GIRGIS CM,WONG T,NGU MC,et al.Hypophosphataemic osteomalacia in patients on adefovir dipivoxil[J].J Clin Gastroenterol,2011,45(5):468-473.
|
|
[9]HALL AM,HENDRY BM,NITSCH D,et al.Tenofovir-associated kidney toxicity in HIV-infected patients:a review of the evidence[J].Am J Kidney Dis,2011,57(5):773-780.
|
|
[10]GARA N,ZHAO X,COLLINS MT,et al.Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B[J].Aliment Pharmacol Ther,2012,35(11):1317-1325.
|
|
[11]KIM YJ,CHO HC,SINN DH,ET AL.Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients[J].J Gastroenterol Hepatol,2012,27(2):306-312.
|
|
[12]MARCELLIN P GE,FLISIAK R,TRINH H,et al.Long-term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance:8 year results from two phase 3 trials[J].Hepatology,2014,60:313A-314A.
|
|
[13]KDIGO.Chapter 1:Definition and classification of CKD[J].Kidney Int Suppl(2011),2013,3(1):19-62.
|
|
[14]LI LS.Nephrology in China[M].Beijing:People's Military Medical Press,2008:14-16.(in Chinese)黎磊石.中国肾脏病学[M].北京:人民军医出版社,2008:14-16.
|
|
[15]Chronic Kidney Disease Prognosis Consortium,MATSUSHITA K,van der VELDE M,et al.Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts:a collaborative meta-analysis[J].Lancet,2010,375(9731):2073-2081.
|
|
[16]WEN CP,MATSUSHITA K,CORESH J,et al.Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar[J].Kidney Int,2014,86(4):819-827.
|
|
[17]SHIN JH,KWON HJ,JANG HR,et al.Risk factors for renal functional decline in chronic hepatitis B patients receiving oral antiviral agents[J].Medicine(Baltimore),2016,95(1):e2400.
|
|
[18]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
|
[19]SARIN SK,KUMAR M,LAU GK,et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update[J].Hepatol Int,2016,10(1):1-98.
|
|
[20]WU X,CAI S,LI Z,et al.Potential effects of telbivudine and entecavir on renal function:a systematic review and meta-analysis[J].Virol J,2016,13(1):64.
|
|
[21]SAADAH OI,SINDI HH,BIN-TALIB Y,et al.Entecavir treatment of children 2-16 years of age with chronic hepatitis B infection[J].Arab J Gastroenterol,2012,13(2):41-44.
|
|
[22]JONAS MM,CHANG MH,SOKAL E,et al.Randomized controlled trial of entecavir versus placebo in children with HBe Ag-positive chronic hepatitis B[J].Hepatology,2016,63(2):377-387.
|
|
[23]SUN J,XIE Q,TAN D,et al.The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients:a randomized,controlled study[J].Hepatology,2014,59(4):1283-1292.
|
|
[24]LIAW YF,KAO JH,PIRATVISUTH T,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012 update[J].Hepatol Int,2012,6(3):531-561.
|
|
[25]QI X,WANG J,CHEN L,et al.Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B[J].Medicine(Baltimore),2015,94(15):e646.
|
|
[26]QI X,WANG JY,MAO RC,et al.Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B:a prospective cohort study in China[J].J Viral Hepat,2015,22(1):46-54.
|
|
[27]CAI JF,DOU XL,WEN YB,et al.Analysis on relevant factors for hepatitis B virus-associated glomerulonephritis[J].Chin J Nephrol,2011,27(2):96-99.(in Chinese)蔡建芳,窦晓丽,文煜冰,等.乙型肝炎病毒相关性肾炎的相关因素分析[J].中华肾脏病杂志,2011,27(2):96-99.
|
|
[28]LIM YS,LARSON TS,BENSON JT,et al.Serum sodium,renal function,and survival of patients with end-stage liver disease[J].J Hepatol,2010,52(4):523-528.
|
|
[29]WHO Guidelines Approved by the Guidelines Review Committee.Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection[J].Geneva:World Health Organization,2015.
|
|
[30]GAO BX,HE Y,LI GX,et al.Analysis of relationship of chronic severe hepatitis with hepatorenal syndrome[J].J Clin Hepatol,2011,27(7):749-751.(in Chinese)高宝秀,贺勇,李贵星,等.慢性重型肝炎并发肝肾综合征的相关因素分析[J].临床肝胆病杂志,2011,27(7):749-751.
|
|
[31]PIPILI C,CHOLONGITAS E,PAPATHEODORIDIS G.Review article:nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease[J].Aliment Pharmacol Ther,2014,39(1):35-46.
|
|
[32]LEE S,PARK JY,SONG K,et al.Comparison of the effects of telbivudine and entecavir treatment on estimated glomerular filtration rate in patients with chronic hepatitis B[J].Gut Liver,2015,9(6):776-783.
|
|
[33]CHAN HL,CHEN YC,GANE EJ,et al.Randomized clinical trial:efficacy and safety of telbivudine and lamivudine in treatmentna6ve patients with HBV-related decompensated cirrhosis[J].J Viral Hepat,2012,19(10):732-743.
|
|
[34]SHOUVAL D,SHIBOLET O.Immunosuppression and HBV reactivation[J].Semin Liver Dis,2013,33(2):167-177.
|
|
[35]MANDALM,FAGIUOLI S,FRANCISCI D,et al.Hepatitis B in immunosuppressed cancer patients:pathogenesis,incidence and prophylaxis[J].Crit Rev Oncol Hematol,2013,87(1):12-27.
|
|
[36]CHOLONGITAS E,PAPATHEODORIDIS GV.High genetic barrier nucleos(t)ide analogue(s)for prophylaxis from hepatitis B virus recurrence after liver transplantation:a systematic review[J].Am J Transplant,2013,13(2):353-362.
|
|
[37]YI NJ,CHOI JY,SUH KS,et al.Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin[J].J Gastroenterol,2013,48(12):1401-1410.
|
|
[38]PERRELLA A,LANZA AG,PISANIELLO D,et al.Telbivudine prophylaxis for hepatitis B virus recurrence after liver transplantation improves renal function[J].Transplant Proc,2014,46(7):2319-2321.
|
|
[39]CHOLONGITAS E,VASILIADIS T,GOULIS I,et al.Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease[J].J Viral Hepat,2015,22(7):574-580.
|
|
[40]YAP DY,CHAN TM.The use of telbivudine in kidney transplant recipients with chronic hepatitis b virus infection-A preliminary experience[J].Nephrology(Carlton),2016,21(5):438-441.
|
|
[41]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:liver transplantation[J].J Hepatol,2016,64(2):433-485.
|
|
[42] Expert Panel of Antiviral Therapy for Hepatocellular Carcinoma.Expert consensus on antiviral therapy to hepatitis B/C virus-related hepatocellular carcinoma[J].J Clin Hepatol,2014,30(5):390-395.(in Chinese)中华医学会肝病学分会肝癌学组.HBV/HCV相关性肝细胞癌抗病毒治疗专家建议[J].临床肝胆病杂志,2014,30(5):390-395.
|
|
[43]WU CY,CHEN YJ,HO HJ,et al.Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection[J].JAMA,2012,308(18):1906-1913.
|
|
[44]Ministry of Health of the People’s Republic of China.Diagnosis,management,and treatment of hepatocellular carcinoma(V2011)[J].J Clin Hepatol,2011,27(11):1141-1159.(in Chinese)中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159.
|
|
[45]SUN P,DONG X,CHENG X,et al.Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment:a systematic review and meta-analysis[J].PLo S One,2014,9(7):e102761.
|
|
[46]YIN J,LI N,HAN Y,et al.Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus related hepatocellular carcinoma:a two-stage longitudinal clinical study[J].J Clin Oncol,2013,31(29):3647-3655.
|
|
[47]KIM YW,KWON JH,CHUNG E,et al.Short term virologic efficacies of telbivudine versus entecavir against hepatitis B-related hepatocellular carcinoma[J].Gastroenterol Res Pract,2015,2015:181065.
|
|
[48]GANE EJ,DERAY G,LIAW YF,et al.Telbivudine improves renal function in patients with chronic hepatitis B[J].Gastroenterology,2014,146(1):138-146,e5.
|
|
[49]WANG Y,THONGSAWAT S,GANE EJ,et al.Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B[J].J Viral Hepat,2013,20(4):e37-e46.
|
|
[50] European Association for The Study of The Liver.EASL clinical practice guidelines:Management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.[本文首次发表于:实用肝脏病杂志,2016,19(4):后插1-后插6]
|
PDF下载 ( 274 KB)
本文二维码
下载:
